Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q2 2026 Earnings Presentation
34 slides from Chugai Pharmaceutical's earnings presentation, Jul 24, 2026
Slide 1: Conference on FY2026.12 Q2 Financial Results
Conference on FY2026.12 Q2 Financial Results 24 July 2026 CHUGAI PHARMACEUTICAL CO., LTD.
Slide 2: Important Reminder
Important Reminder Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual resul
Slide 3: Agenda
Agenda 01 FY2026 Q2 Overview President & CEO Dr. Osamu Okuda Executive Vice President, Head of Project & FY2026 Q2 Overview of Development 02 Lifecycle Management Unit Pipeline Tsukasa Kusano FY2026 Q2 Consolidated Financial 03 Director, Executive Vice President & CFO Overview (Core) Iwaaki Taniguch
Slide 4: FY2026 Q2 Overview
FY2026 Q2 Overview President & CEO Dr. Osamu Okuda
Slide 5: Executive Summary
FY2026 Q2 Overview Executive Summary Financial Overview: 2026 Q2 Key Financial Update ◼ Recorded increased revenue and profit. Steady (Core results for the six months ended June 30, 2026) progress towards achieving the full year forecast Sales ◼ Steady domestic and overseas sales, led by JPY 566.5bn
Slide 6: Topline Overview
FY2026 Q2 Overview Topline Overview ◼ Domestic sales Increased YoY. Mainstay products 【 Billions of JPY】 (Vabysmo, Polivy, Enspryng, Overseas sales Phesgo) and new products +40.5 (Elevidys, Lunsumio) performed +15.5 favorably, despite the effects of Export unit Sales volume the NHI drug price revisi
Slide 7: Update on Chugai-Originated Global New Products
FY2026 Q2 Overview Update on Chugai-Originated Global New Products ◼ Market penetration advancing for two Chugai-originated global new products important to short- and medium-term growth Licensed out to Galderma Licensed out to Eli Lilly NEMLUVIO: Penetration advancing mainly FOUNDAYO: Expanding ins
Slide 8: Progress on Early Development of Chugai Originated Projects
FY2026 Q2 Overview Progress on Early Development of Chugai Originated Projects ◼ Steady advancement in the early development of Chugai originated projects expected to drive mid- to long-term growth Small molecule project Macrocyclic peptide project AQUA07 : The third macrocyclic peptide REVN24 : Met
Slide 9: Strategic Capital Allocation Toward Creating Shared Value and Shareholder Returns
FY2026 Q2 Overview Strategic Capital Allocation Toward Creating Shared Value and Shareholder Returns ◼ Pursue business investments necessary for sustainable growth more proactively, while continuing to provide stable shareholder returns, based on our capital allocation policy Capital Allocation Poli
Slide 10: FY2026 Q2 Overview of Development Pipeline
FY2026 Q2 Overview of Development Pipeline Executive Vice President, Head of Project & Lifecycle Management Unit Tsukasa Kusano
Slide 11: Q2 Topics (1/2)
FY2026 Q2 Overview of Development Pipeline Q2 Topics (1/2) Alecensa Advanced or recurrent ALK fusion gene-positive solid tumors (Japan) May 2026 Approved Avastin Neurofibromatosis type 2 June 2026 Rituxan Adult-onset frequently relapsing or steroid-dependent nephrotic syndrome June 2026 Enspryng Thy
Slide 12: Q2 Topics (2/2)
FY2026 Q2 Overview of Development Pipeline Q2 Topics (2/2) Removed tominersen Huntington's disease: Discontinuation of development － from Pipeline AVMAPKI* P1b/2a RAMP205 study (metastatic pancreatic ductal adenocarcinoma ) June 2026 Readout divarasib P3 Krascendo 1 study (non-small cell lung cancer
Slide 13: 2026: Key R&D Milestones
FY2026 Q2 Overview of Development Pipeline 2026: Key R&D Milestones Underlined and bolded: Changes since April 24, 2026 Product Indication / Study name Progress Projects to be Alecensa Advanced or recurrent ALK fusion gene-positive solid tumors（Japan） Approved Approved Lunsumio + Polivy Relapsed or
Slide 14: AQUA07 (Allosteric ALK inhibitor)
FY2026 Q2 Overview of Development Pipeline AQUA07 (Allosteric ALK inhibitor) ◼ The third clinical-stage project applying our macrocyclic peptide drug discovery platform technology "SnipeTide." Patient dosing for ALK-positive non-small cell lung cancer (NSCLC) is expected to commence shortly. ◼ Unlik
Slide 15: PiaSky: atypical Hemolytic Uremic Syndrome (aHUS)
FY2026 Q2 Overview of Development Pipeline PiaSky: atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 study: COMMUTE-a (Adult and adolescent), COMMUTE-p (Pediatric): 2026 European Renal Association Congress ◼ Favorable primary endpoint results: Both trials demonstrated solid complete TMA response (cT
Slide 16: DONQ52 Development Status
FY2026 Q2 Overview of Development Pipeline DONQ52 Development Status ◼ Accelerated development through Go/No-Go decision making; P2a study ongoing for celiac disease in the U.S., Australia, and New Zealand ◼ A multispecific antibody that binds to more than 25 gluten peptides ◼ Inhibits T-cell activa
Slide 17: Projected Submissions (Phase II & Later Programs and Products)
FY2026 Q2 Overview of Development Pipeline Projected Submissions (Phase II & Later Programs and Products) NME Line extension Filed aHUS: atypical hemolytic uremic syndrome BC: breast cancer NSCLC: non-small cell lung cancer r/r DLBCL: relapsed or refractory diffuse large In-house ENSPRYNG ranibizuma
Slide 18: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2)
FY2026 Q2 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2) ★: Changes since April 24, 2026 Generic name/ Mode of Granted rights Development Licensee Stage Indication Progress Action to licensee code KRAS-mutated US: recurrent low-grade ⚫
Slide 19: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2)
FY2026 Q2 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2) Generic name/ Granted Mode of Development Licensee rights to Stage Indication Progress Action code licensee US: Launched ⚫ Obtained US FDA approval as an obesity treatment in Q2
Slide 20: FY2026 Q2 Consolidated Financial Overview (Core)
FY2026 Q2 Consolidated Financial Overview (Core) Director, Executive Vice President & CFO Iwaaki Taniguchi
Slide 21: P/L Jan – Jun (Year on Year)
FY2026 Q2 Consolidated Financial Overview (Core) P/L Jan – Jun (Year on Year) ◼ Domestic sales (Billions of JPY) 2025 2026 Growth Increase due to growth of mainstay products and new products, despite decrease due to the NHI drug price Revenue 578.5 663.3 + 84.8 + 14.7% revisions and the market penet
Slide 22: Sales Jan – Jun (Year on Year)
FY2026 Q2 Consolidated Financial Overview (Core) Sales Jan – Jun (Year on Year) Sales by Disease Area, Sales by Product, Year on Year Year on Year (Billions of JPY) ( ): Actual sales in FY2026, %: Year-on-year percentage change +55.1, +10.8% *Included in Others in the Specialty area **Patient Share
Slide 23: Operating Profit Jan – Jun (Year on Year)
FY2026 Q2 Consolidated Financial Overview (Core) Operating Profit Jan – Jun(Year on Year) Increase in Increase in (Billions of JPY) cost of sales various costs and increase in other -20.7 Overseas sales operating +29.8 income +40.5 -7.0 Increase in +18.8 other revenue Domestic sales Impact of +14.6
Slide 24: Structure of Costs and Profit by Quarter
FY2026 Q2 Consolidated Financial Overview (Core) Structure of Costs and Profit by Quarter (Billions of JPY) ◼ Year on Year (vs. 2025 Q2) % of Revenue (% of sales for Cost to sales ratio: increase due to a change in product mix, cost of sales) etc. R&D: increase due to investments into drug discovery
Slide 25: Structure of Revenue by Quarter
FY2026 Q2 Consolidated Financial Overview (Core) Structure of Revenue by Quarter (Billions of JPY) ◼ Year on Year (vs. 2025 Q2) % of Revenue Domestic sales: increase due to sales growth of new products Overseas sales: increase in sales of Actemra due to the timing of shipment Other revenue: signific
Slide 26: P/L Jan – Jun (vs. Forecast)
FY2026 Q2 Consolidated Financial Overview (Core) P/L Jan – Jun (vs. Forecast) Actual Forecast 2025 ◼ Domestic sales (Billions of JPY) 2026 2026 Mostly in line with the forecast Progress Progress* Jan - Jun Jan - Dec ◼ Overseas sales Revenue 663.3 1,345.0 49.3% 46.0% Mostly in line with the forecast
Slide 27: Sales Jan – Jun (vs. Forecast)
FY2026 Q2 Consolidated Financial Overview (Core) Sales Jan – Jun (vs. Forecast) Actual Forecast 2025 Actual Forecast 2025 (Billions of JPY) 2026 2026 (Billions of JPY) 2026 2026 Progress Progress * Progress Progress * Jan - Jun Jan - Dec Jan - Jun Jan - Dec Sales 566.5 1,100.0 51.5% 47.4% Specialty
Slide 28: Impact from Foreign Exchange Jan – Jun
FY2026 Q2 Consolidated Financial Overview (Core) Impact from Foreign Exchange Jan – Jun vs.2025 vs.2026 2025 2026 2026 2026 2026 Actual rate Forecast rate Exchange Actual Forecast Actual rate** Market Forecast (Billions of JPY) Rate rate** rate Jan –Jun average rate Jan - Jun Jan - Jun rate*** Jan -
Slide 29: Financial Position as of June 30 (vs. 2025 Year End)
FY2026 Q2 Consolidated Financial Overview (Core) Financial Position as of June 30 (vs. 2025 Year End) (Billions of JPY) Total assets 2,468.6 -18.7 2,449.9 ⚫ Decrease in net working capital Total liabilities -442.9 +20.6 -422.3 Decrease due to decrease in other account 2,025.7 Total net assets 2,027.
Slide 30: Net Cash (vs. 2025 Year End)
FY2026 Q2 Consolidated Financial Overview (Core) Net Cash (vs. 2025 Year End) (Billions of JPY) Total investment ■ Operating profit after adjustment * +339.1 Income taxes Operating profit * +319.6 +12.4 -35.9 paid, etc. Decrease in * +18.7 net working -88.7 Dividends Depreciation, amortization and i
Slide 31: P/L Jan – Jun (Non-core adjustment)
FY2026 Q2 Consolidated Financial Overview (Core) P/L Jan – Jun (Non-core adjustment) Non-core items Non-core items IFRS Core (Billions of JPY) Intangible results Others results Factors affected operating profit assets Revenue 663.3 663.3 ◼ Intangible assets Sales 566.5 566.5 Amortization +1.2 Other
Slide 32: Current Status / Plan for Major Investments
FY2026 Q2 Consolidated Financial Overview (Core) Current Status / Plan for Major Investments Planned investment ～2025 2026 2027 2028 2029 2030 2031～ Period* Investment Total amount Unit to-date Utsunomiya plant UT3: Manufacture bio drug substance for middle to later- stage clinical 37.4 34.7 billion
Slide 33: Contacts
Contacts Corporate Communications Dept. For Media: Media Relations Group Tel： +81 (0)3-3273-0881 E-mail： pr@chugai-pharm.co.jp Person in Naoki Kouzai, Hitomi Shiobara, Atsuki Hirano, Ikue Miyazawa, charge： Kaho Izumi For Investors: Investor Relations Group Tel： +81 (0)3-3273-0554 E-mail： ir@chugai-p
Slide 34: INNOVATION BEYOND IMAGINATION
INNOVATION BEYOND IMAGINATION (OJ! CHUGAI PHARMACEUTICAL A member of the Roche group
Chugai Pharmaceutical — Q2 2026 Earnings Presentation on 6ix